Abstract
According to Sapporo criteria revised by the Sydney conference, antiphospholipid syndrome (APS) is defined by the association of thromboembolic or obstetrical events with biological markers. These biological markers are lupus anticoagulant, anti-cardiolipin antibodies and anti-β2Gp1 antibodies. The main issue of APS remains the assessment of the clinical risk. Clinical scores have been developed but they are rarely used in clinical practice. Biological tests such as thrombin generation assay or anti-domain 1 of β2Gp1 antibodies seem to be promising. This review describes the biological diagnosis APS and discussed prediction of potential prediction tools for the prediction of clinical thromboembolic events.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
